SCHEMBL6350864

SCHEMBL6350864

CC(C)[C@H](C(N)=O)N(CC(=O)c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 11/20 0.47
NR1I2 O75469 1/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
USP2 O75604 1/20 0.40
KMT2A Q03164 2/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
CES1 P23141 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
AGTR1 P30556 1/20 0.38
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ADRA2C P18825 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359179 1.00 TRPM8 (0.47) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6351225 0.92 CYP3A4 (0.47) TRPM8NR1I2KDM4EALDH1A1KMT2A
SCHEMBL6359454 0.92 CYP3A4 (0.47) TRPM8NR1I2KDM4EALDH1A1KMT2A
SCHEMBL6356063 0.90 L3MBTL1 (0.49) TRPM8KDM4EALDH1A1KMT2AMAPT
SCHEMBL6347733 0.88 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6354208 0.88 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6347856 0.88 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6359362 0.88 TSHR (0.42) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6358298 0.88 TSHR (0.42) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6350699 0.88 ALDH1A1 (0.47) ALDH1A1KMT2AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 TRPM8 1934/4885NR1I2 426/4885KDM4E 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.